A fully implantable brain-computer interface (BCI) with onboard processing to control a robotic gait exoskeleton as a walking aid for individuals with chronic spinal cord injury (SCI). This technology would alleviate SCI patient’s dependence on wheel chairs, reducing the risk of secondary medical complications that account for an estimated $50 billion/year in healthcare costs.
Patients with spinal cord injury suffer the inability to control their lower extremities, most importantly, the ability to walk on their own. To manage an independent lifestyle, patients can utilize a wheel chair for mobility. Unfortunately, prolonged wheel chair usage can cause pressure ulcers, blood clots and affect patient metabolism. Cap-based electroencephalogram, a minimally invasive cap device worn over the skull that measures brain electrical activity to control a prosthesis, has been suggested as an alternative to wheel chairs. Despite their utility, minimally invasive brain control prosthesis system hold many limitations. Cap-based electroenecephalograms have a limited ability to map specific brain signals to prosthesis motion, are cumbersome to put on, and are not aesthetically pleasing. Therefore, there exists a need for a precise and socially acceptable form of brain-controlled prosthetic interface to alleviate spinal cord injury patients from the social and secondary health problems associated with prolonged wheel chair usage.
UCI researchers have developed a battery powered electrocorticogram brain computer interface, a fully implantable device that sits underneath a patient’s skull to directly measure the electrical activity of the brain to control a prosthesis. Since the device detection circuitry sits closer to the brain. It can precisely map brain activity to controlled movements of a prosthesis, resolving one of the drawbacks of current systems. This device does not require mounting and dismounting, and is hidden away out of plane sight. It has also been shown that the device measures and produces five years of reproducible control signal that is within FDA implantable compliance.
|United States Of America||Issued Patent||11,278,226||03/22/2022||2016-344|
Additional Patent Pending